Artiva Biotherapeutics (ARTV) Minority Interest (2023 - 2024)

Artiva Biotherapeutics (ARTV) reported Minority Interest of $96.8 million for Q2 2024, down 19.12% quarter-over-quarter from $119.6 million in Q4 2023.

Artiva Biotherapeutics (ARTV) Minority Interest (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has 2 years of Minority Interest data on file, last reported at $96.8 million in Q2 2024.

  • Minority Interest for Q2 2024 came in at $96.8 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was $96.8 million (changed N/A YoY), and the FY2023 annual result was $119.6 million, changed N/A from the prior year.
  • Minority Interest retreated to $96.8 million in Q2 2024 per ARTV's latest filing, from $119.6 million in the prior quarter.
  • Over five years, Minority Interest peaked at $119.6 million in Q4 2023 and troughed at $96.8 million in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Artiva Biotherapeutics 241.85 Mn 241.85 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2024 96.77 Mn
Dec 31, 2023 119.65 Mn